CareDx, Inc (CDNA) Q2 FY26 Earnings Call

Strong transplant execution and raised guidance support growth, while NavDx integration and billing execution remain key variables [5][13][16].

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Length47 minutes
EPS$0.17

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26

All CDNA earnings ยท Back to CDNA overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.